Running a biotech company means taking risks — deciding where to invest, for example, or what scientific targets to chase.
However, the sector faces another kind of risk, with a new administration in charge in Washington.
That’s the message Biogen chief executive Chris Viehbacher conveyed to Massachusetts Gov. Maura Healey, during a Q&A session following her speech on Thursday at an Associated Industries of Massachusetts event in Waltham. Earlier in the week, the National Institutes of Health and other federal health agencies cancelled a flurry of meetings, as the incoming Trump administration gets settled.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in